Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 251

Results For "ABLE"

5292 News Found

PrecisionLife identifies first detailed genetic risk factors for long COVID
News | July 19, 2023

PrecisionLife identifies first detailed genetic risk factors for long COVID

Long COVID is a debilitating chronic condition that has affected over 100 million people globally


Helping Hand Foundation launches screening for glaucoma in Hyderabad
Healthcare | July 19, 2023

Helping Hand Foundation launches screening for glaucoma in Hyderabad

First of its kind screening for Glaucoma at grass root level over 10k screened already


Strand Life Sciences expands sequencing facility
Medical Device | July 19, 2023

Strand Life Sciences expands sequencing facility

The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all


Lonza launches new cell culture media system TheraPRO
News | July 18, 2023

Lonza launches new cell culture media system TheraPRO

The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production


JeNaCell launches wound dressing epicite balance for chronic wounds
News | July 17, 2023

JeNaCell launches wound dressing epicite balance for chronic wounds

Moist wound dressing for chronic wound treatment now available in Germany


Briefs: Link Pharma Chem and Zydus
News | July 11, 2023

Briefs: Link Pharma Chem and Zydus

USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad


NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData
Drug Approval | July 11, 2023

NMPA approval for first BCMA CAR-T Therapy paves way for more multiple myeloma cell therapies, says GlobalData

Approval to dramatically change CAR-T therapies landscape


Sumitomo Pharma America launches as new combined organization
News | July 11, 2023

Sumitomo Pharma America launches as new combined organization

SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets